Bissonnette F, Masip JM, Kadoch IJ, et al. - In this multicenter, open label, exploratory study, researchers sought to assess the safety profile and the number of usable blastocysts on day 5 and on day 6 after treatment with an individualized dosing regimen of a follitropin delta and highly purified human menopausal gonadotropin (HP-hMG) for controlled ovarian stimulation. The sample consisted of 110 patients (aged 18–40 years). The optimization of the ovarian response during in vitro fertilization using a mixed individualized dosing protocol for follitropin delta and HP-hMG resulted in an increased risk of mild OHSS, which did not involve medical intervention or hospitalization, in a statistically significant number of usable blastocysts on days 5 and 6.